Peter Nash

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Joining the discussion are Peter Nash, an expert on JAK inhibitors, Mrinalini Dey, a rheumatologist focusing on methotrexate side effects, and Chris Wincup, who dives into neuropsychiatric lupus. They reveal fascinating insights into JAK inhibitors, their safety, and the importance of vaccinations. Dey shifts perspectives on methotrexate side effects, while she and Wincup emphasize recognizing neuropsychiatric symptoms in lupus, advocating for improved communication and awareness in patient care.